A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC288 in the Treatment of Soli… (NCT07537881) | Clinical Trial Compass
Not Yet RecruitingPhase 1/2
A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC288 in the Treatment of Solid Tumors
China326 participantsStarted 2026-04-30
Plain-language summary
The primary objective is to evaluate the safety and tolerability of RC288; determine the maximum tolerated dose (MTD) and/or maximum administered dose (MAD) of RC288; and determine the recommended phase 2 dose (RP2D), and assess the efficacy of RC288 at the RP2D dose;
Who can participate
Age range
18 Years – 75 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Voluntarily participate in this study, sign the informed consent form, and be able to adhere to the study protocol;
. Age between 18 and 75 years (including 18 and 75 years);
. ECOG PS score of 0 or 1;
. Expected survival ≥12 weeks;
. According to RECIST v1.1 criteria, based on imaging examinations, there is at least one measurable target lesion;
. Sufficient bone marrow, liver, kidney, and blood clotting function
Exclusion criteria
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Dose-Limiting Toxicity (DLT)
Timeframe: 24 months
2
Incidence and severity of adverse events/serious adverse events (graded according to NCI CTCAE v6.0)
Timeframe: 24 months
3
Determine RP2D of RC288
Timeframe: 24 months
4
MTD and/or MAD
Timeframe: 24 months
5
Prostate Cancer Cohort: Investigator assessed ORR according to RECIST v1.1 criteria and PCWG3 criteria
Timeframe: 24 months
6
Non-Prostate Cancer Cohort: Investigator assessed ORR according to RECIST v1.1 criteria